Origins of BL genes
Tier 1 BL genes
32 total
Tier 2 BL genes
72 total
Tier 3 BL genes
70 total
| Gene | Summary | First BL study | Other entities | QC result |
|---|---|---|---|---|
| ACAD9 | Tier 3 GE1 | Love et al | FAIL | |
| ACE | Tier 3 GE1 | Love et al | 6 | FAIL |
| ALPK2 | Tier 3 GE13 | Panea et al | FAIL | |
| ATP2C2 | Tier 3 GE1 | Love et al | FAIL | |
| BRAF | Tier 3 GE1, FE71 | Love et al | 72 | FAIL |
| BRD4 | Tier 3 GE1 | Love et al | 6 | FAIL |
| BTG2 | Tier 3 GE1, aSHM | Love et al | 9,10 | FAIL |
| C6orf27 | Tier 3 GE1 | Love et al | FAIL | |
| CAD | Tier 3 GE1 | Love et al | 6 | FAIL |
| CCT6B | Tier 3 GE1 | Love et al | FAIL | |
| CD79B | Tier 3 GE13, FE73 | Panea et al | 9,73 | FAIL |
| CDH17 | Tier 3 GE1 | Love et al | FAIL | |
| COL4A2 | Tier 3 GE1 | Love et al | FAIL | |
| CTCF | Tier 3 GE13 | Panea et al | FAIL | |
| CYB5D1 | Tier 3 GE1 | Love et al | FAIL | |
| CYP4F22 | Tier 3 GE1 | Love et al | FAIL | |
| DLGAP1 | Tier 3 GE1 | Love et al | 6 | FAIL |
| DNMT1 | Tier 3 GE13 | Panea et al | FAIL | |
| DTX1 | Tier 3 GE1, aSHM | Love et al | 4,6,74 | FAIL |
| EIF2C4 | Tier 3 GE1 | Love et al | FAIL | |
| EML2 | Tier 3 GE1 | Love et al | FAIL | |
| ENTPD3 | Tier 3 GE1 | Love et al | FAIL | |
| EPHB2 | Tier 3 GE1 | Love et al | FAIL | |
| ETS1 | Tier 3 GE13, aSHM | Panea et al | 10 | FAIL |
| FAM129B | Tier 3 GE1 | Love et al | FAIL | |
| FGFR3 | Tier 3 GE1 | Love et al | FAIL | |
| FTCD | Tier 3 GE1 | Love et al | FAIL | |
| FZD3 | Tier 3 GE13 | Panea et al | FAIL | |
| GRIK5 | Tier 3 GE1 | Love et al | FAIL | |
| HIST1H1C | Tier 3 GE13, aSHM | Panea et al | 10 | FAIL |
| HIST1H2AG | Tier 3 GE13 | Panea et al | 3,4,28 | FAIL |
| HIST1H2AM | Tier 3 GE13, aSHM | Panea et al | 3,41 | FAIL |
| HIST1H2BK | Tier 3 GE13, aSHM | Panea et al | 4,6 | FAIL |
| HIST1H3H | Tier 3 GE13 | Panea et al | FAIL | |
| HIST1H3J | Tier 3 GE13 | Panea et al | FAIL | |
| ICK | Tier 3 GE1 | Love et al | FAIL | |
| ITPR3 | Tier 3 GE1 | Love et al | 46 | FAIL |
| KCNK10 | Tier 3 GE13 | Panea et al | FAIL | |
| KIFC3 | Tier 3 GE1 | Love et al | FAIL | |
| MAP3K6 | Tier 3 GE1 | Love et al | FAIL | |
| MME | Tier 3 GE13 | Panea et al | FAIL | |
| MTOR | Tier 3 GE13, FE75 | Panea et al | 6 | FAIL |
| MYH10 | Tier 3 GE1 | Love et al | FAIL | |
| NOTCH1 | Tier 3 GE1, FE76 | Love et al | 4,33,77 | FAIL |
| NRXN2 | Tier 3 GE1 | Love et al | 6 | FAIL |
| PABPC4L | Tier 3 GE13 | Panea et al | FAIL | |
| PC | Tier 3 GE1 | Love et al | FAIL | |
| PCDHA11 | Tier 3 GE13 | Panea et al | FAIL | |
| PDZRN3 | Tier 3 GE13 | Panea et al | 6 | FAIL |
| PIK3R1 | Tier 3 GE13 | Panea et al | 6 | FAIL |
| POLRMT | Tier 3 GE1 | Love et al | FAIL | |
| POR | Tier 3 GE1 | Love et al | FAIL | |
| PRSS22 | Tier 3 GE1 | Love et al | FAIL | |
| PTPRN | Tier 3 GE1 | Love et al | FAIL | |
| PXDNL | Tier 3 GE13 | Panea et al | FAIL | |
| RBP3 | Tier 3 GE1 | Love et al | 29 | FAIL |
| RET | Tier 3 GE1 | Love et al | 68 | FAIL |
| SALL3 | Tier 3 GE1 | Love et al | 64 | FAIL |
| SAPS2 | Tier 3 GE1 | Love et al | FAIL | |
| SBF1 | Tier 3 GE1 | Love et al | FAIL | |
| SF3B1 | Tier 3 GE1, FE78 | Love et al | 23 | FAIL |
| SHANK1 | Tier 3 GE1 | Love et al | FAIL | |
| SLC29A2 | Tier 3 GE1 | Love et al | FAIL | |
| SNTB2 | Tier 3 GE13 | Panea et al | FAIL | |
| SYNGAP1 | Tier 3 GE1 | Love et al | FAIL | |
| TBC1D9B | Tier 3 GE1 | Love et al | FAIL | |
| TIGD6 | Tier 3 GE1 | Love et al | FAIL | |
| TPST2 | Tier 3 GE1 | Love et al | FAIL | |
| WDR7 | Tier 3 GE13 | Panea et al | FAIL | |
| ZNF229 | Tier 3 GE1 | Love et al | FAIL |
References
1.
Love
C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi
WWL, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L,
Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader
MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A,
Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations
in Burkitt lymphoma. Nat Genet. 2012 Dec;44(12):1321–1325.
PMCID: PMC3674561
2.
Barisic D, Chin CR, Meydan C, Teater M, Tsialta
I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE,
Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl
C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A. ARID1A
orchestrates SWI/SNF-mediated
sequential binding of transcription factors with ARID1A
loss driving pre-memory B cell fate and
lymphomagenesis. Cancer Cell. 2024 Apr 8;42(4):583–604.e11.
3.
Krysiak K, Gomez F, White BS, Matlock M, Miller
CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR,
Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA.
Recurrent somatic mutations affecting B-cell
receptor signaling pathway genes in follicular lymphoma. Blood. 2017 Jan
26;129(4):473–483. PMCID: PMC5270390
4.
Rossi D, Trifonov V, Fangazio M, Bruscaggin A,
Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C,
Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A,
Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R,
Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti
F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R,
Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G. The coding genome
of splenic marginal zone lymphoma: Activation of NOTCH2 and
other pathways regulating marginal zone development. J Exp Med. 2012 Aug
27;209(9):1537–1551. PMCID: PMC3428941
5.
Wienand K, Chapuy B, Stewart C, Dunford AJ, Wu
D, Kim J, Kamburov A, Wood TR, Cader FZ, Ducar MD, Thorner AR, Nag A,
Heubeck AT, Buonopane MJ, Redd RA, Bojarczuk K, Lawton LN, Armand P,
Rodig SJ, Fromm JR, Getz G, Shipp MA. Genomic analyses of flow-sorted
Hodgkin Reed-Sternberg cells reveal complementary
mechanisms of immune evasion. Blood Adv. 2019 Dec 10;3(23):4065–4080.
PMCID: PMC6963251
6.
Zhang J, Grubor V, Love CL, Banerjee A,
Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G,
Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C,
Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A,
Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J,
Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse
large B-cell lymphoma. Proceedings of the
National Academy of Sciences of the United States of America.
2013;110:1398–1403. PMCID: PMC3557051
7.
Grande BM, Gerhard DS, Jiang A, Griner NB,
Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K,
Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA,
Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL,
He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE,
Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG,
Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J,
Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH,
Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery
of somatic coding and noncoding mutations in pediatric endemic and
sporadic Burkitt lymphoma. Blood. 2019;133(12):1313–1324.
PMCID: PMC6428665
8.
Mascle X, Albagli O, Lemercier C. Point mutations in
BCL6 DNA-binding domain reveal distinct
roles for the six zinc fingers. Biochem Biophys Res Commun. 2003 Jan
10;300(2):391–396.
9.
Dreval K, Hilton LK, Cruz M, Shaalan H,
Ben-Neriah S, Boyle M, Collinge B, Coyle KM, Duns G, Farinha P, Grande
BM, Meissner B, Pararajalingam P, Rushton CK, Slack GW, Wong J, Mungall
AJ, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genetic
subdivisions of follicular lymphoma defined by distinct coding and
noncoding mutation patterns. Blood. 2023 Aug 10;142(6):561–573. PMCID:
PMC10644066
10.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R,
Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M,
Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme
MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus
D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ,
Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao
Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J,
Horsman DE, Moore R, Jones SJM, Connors JM, Hirst M, Gascoyne RD, Marra
MA. Frequent mutation of histone-modifying genes in
non-Hodgkin lymphoma. Nature. 2011 Jul
27;476(7360):298–303. PMCID: PMC3210554
11.
Baliñas-Gavira C, Rodríguez MI, Andrades Á,
Cuadros M, Álvarez-Pérez J, Álvarez-Prado ÁF, Yébenes VG de,
Sanchez-Hernandez S, Fernández-Vigo E, Muñoz J, Martín F, Ramiro A,
Martinez-Climent J, Medina P. Frequent mutations in
the amino-terminal domain of BCL7A impair its tumor
suppressor role in DLBCL. Leukemia. 2020;1–14.
12.
Reichel J, Chadburn A, Rubinstein PG,
Giulino-Roth L, Tam W, Liu Y, Gaiolla R, Eng K, Brody J, Inghirami G,
Carlo-Stella C, Santoro A, Rahal D, Totonchy J, Elemento O, Cesarman E,
Roshal M. Flow
sorting and exome sequencing reveal the oncogenome of primary
Hodgkin and Reed-Sternberg cells. Blood.
2015 Feb 12;125(7):1061–1072.
13.
Panea R, Love C, Shingleton JR, Reddy A, Bailey
J, Moormann A, Otieno J, Ong’echa J, Oduor C, Schroêder K, Masalu N,
Chao N, Agajanian M, Major M, Fedoriw Y, Richards K, Rymkiewicz G, Miles
R, Alobeid B, Bhagat G, Flowers C, Ondrejka S, Hsi E, Choi W, Au-Yeung
R, Hartmann W, Lenz G, Meyerson H, Lin YY, Zhuang Y, Luftig M, Waldrop
A, Dave T, Thakkar D, Sahay H, Li G, Palus B, Seshadri V, Kim S,
Gascoyne R, Levy S, Mukhopadhyay M, Dunson D, Dave S. The whole genome
landscape of Burkitt lymphoma subtypes. Blood. 2019;
14.
Richter J, Schlesner M, Hoffmann S, Kreuz M,
Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH,
Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages
S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO,
Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S,
Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik
R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Möller P,
MacLeod RAF, Pott C, Schreiber S, Trümper L, Loeffler M, Stadler PF,
Lichter P, Eils R, Küppers R, Hummel M, Klapper W, Rosenstiel P,
Rosenwald A, Brors B, Siebert R, ICGC MMML-Seq Project. Recurrent mutation of the
ID3 gene in Burkitt lymphoma identified by
integrated genome, exome and transcriptome sequencing. Nat Genet.
2012 Dec;44(12):1316–1320.
15.
Schmitz R, Young RM, Ceribelli M, Jhavar S,
Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell
J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P,
Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E,
Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI,
Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S,
Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.
Burkitt lymphoma pathogenesis and therapeutic targets from structural
and functional genomics. Nature. 2012 Oct 4;490(7418):116–120. PMCID: PMC3609867
16.
Desch AK, Hartung K, Botzen A, Brobeil A,
Rummel M, Kurch L, Georgi T, Jox T, Bielack S, Burdach S, Classen CF,
Claviez A, Debatin KM, Ebinger M, Eggert A, Faber J, Flotho C, Frühwald
M, Graf N, Jorch N, Kontny U, Kramm C, Kulozik A, Kühr J, Sykora KW,
Metzler M, Müller HL, Nathrath M, Nüßlein T, Paulussen M, Pekrun A,
Reinhardt D, Reinhard H, Rössig C, Sauerbrey A, Schlegel PG, Schneider
DT, Scheurlen W, Schweigerer L, Simon T, Suttorp M, Vorwerk P, Schmitz
R, Kluge R, Mauz-Körholz C, Körholz D, Gattenlöhner S, Bräuninger A. Genotyping circulating
tumor DNA of pediatric Hodgkin lymphoma.
Leukemia. 2020 Jan;34(1):151–166.
17.
Jallades L, Baseggio L, Sujobert P, Huet S,
Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado
D, Levy N, Béroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles
G, Traverse-Glehen A. Exome sequencing identifies recurrent
BCOR alterations and the absence of KLF2,
TNFAIP3 and MYD88 mutations in splenic diffuse
red pulp small B-cell lymphoma.
Haematologica. 2017 Oct;102(10):1758–1766. PMCID: PMC5622860
18.
Pasqualucci L, Dominguez-Sola D, Chiarenza A,
Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi
D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK,
Dalla-Favera R. Inactivating mutations of acetyltransferase genes in
B-cell lymphoma. Nature. 2011 Mar
10;471(7337):189–195. PMCID: PMC3271441
19.
Duns G, Viganò E, Ennishi D, Sarkozy C, Hung
SS, Chavez E, Takata K, Rushton C, Jiang A, Ben-Neriah S, Woolcock BW,
Slack GW, Hsi ED, Craig JW, Hilton LK, Shah SP, Farinha P, Mottok A,
Gascoyne RD, Morin RD, Savage KJ, Scott DW, Steidl C. Characterization of
DLBCL with a PMBL gene expression
signature. Blood. 2021 Jul 15;138(2):136–148.
20.
Parry M, Rose-Zerilli MJJ, Gibson J, Ennis S,
Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier
DG, Strefford JC. Whole exome sequencing identifies novel recurrently
mutated genes in patients with splenic marginal zone lymphoma. PLoS One.
2013;8(12):e83244. PMCID: PMC3862727
21.
Gong C, Krupka JA, Gao J, Grigoropoulos NF,
Giotopoulos G, Asby R, Screen M, Usheva Z, Cucco F, Barrans S, Painter
D, Zaini NBM, Haupl B, Bornelöv S, Ruiz De Los Mozos I, Meng W, Zhou P,
Blain AE, Forde S, Matthews J, Khim Tan MG, Burke GAA, Sze SK, Beer P,
Burton C, Campbell P, Rand V, Turner SD, Ule J, Roman E, Tooze R,
Oellerich T, Huntly BJ, Turner M, Du MQ, Samarajiwa SA, Hodson DJ. Sequential inverse
dysregulation of the RNA helicases DDX3X and
DDX3Y facilitates MYC-driven
lymphomagenesis. Molecular Cell. 2021;
22.
Mottok A, Hung SS, Chavez EA, Woolcock B,
Telenius A, Chong LC, Meissner B, Nakamura H, Rushton C, Viganò E,
Sarkozy C, Gascoyne RD, Connors JM, Ben-Neriah S, Mungall A, Marra MA,
Siebert R, Scott DW, Savage KJ, Steidl C. Integrative genomic
analysis identifies key pathogenic mechanisms in primary mediastinal
large B-cell lymphoma. Blood. 2019 Sep
5;134(10):802–813.
23.
Reddy A, Zhang J, Davis NS, Moffitt AB, Love
CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg
ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W,
Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y,
Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O,
Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB,
Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava
G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn
A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T,
Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional
Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017
Oct;171(2):481–494.e15. PMCID: PMC5659841
24.
Duan S, Cermak L, Pagan JK, Rossi M, Martinengo
C, di Celle PF, Chapuy B, Shipp M, Chiarle R, Pagano M.
FBXO11 targets BCL6 for degradation and is
inactivated in diffuse large B-cell
lymphomas. Nature. 2011 Nov;
25.
Arthur SE, Jiang A, Grande BM, Alcaide M,
Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L,
Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B,
Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB,
Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P,
Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genome-wide
discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018 Oct 1;9(1):4001.
PMCID: PMC6167379
26.
Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An
J, Jones SJM, Mungall AJ, Zhao Y, Schein J, Steidl C, Connors JM,
Gascoyne RD, Marra MA. Analysis of FOXO1 mutations in
diffuse large B-cell lymphoma. Blood.
2013;121(18):3666–3674. PMCID: PMC3643765
27.
Muppidi J, Schmitz R, Green JA, Green JA, Xiao
W, Larsen AB, Braun S, An J, Xu Y, Rosenwald A, Ott G, Gascoyne R,
Rimsza L, Campo E, Jaffe E, Delabie J, Smeland E, Braziel R, Tubbs R,
Cook J, Weisenburger D, Chan W, Vaidehi N, Staudt L, Cyster J. Loss of signaling via
Gα13 in germinal center B cell-derived
lymphoma. Nature. 2014;516:254–258.
28.
Morin RD, Mungall K, Pleasance E, Mungall AJ,
Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC,
Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A,
Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL,
Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors
JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse
large B-cell lymphoma using whole-genome
sequencing. Blood. 2013 Aug 15;122(7):1256–1265. PMCID: PMC3744992
29.
Lohr JG, Stojanov P, Lawrence MS, Auclair D,
Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL,
Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G,
Stransky N, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A,
Melendez-Zajgla J, Hernández-Lemus E, Schwarz-Cruz y Celis A,
Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES,
Habermann TM, Cerhan JR, Shipp MA, Getz G, Golub TR. Discovery and
prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by
whole-exome sequencing. Proc Natl Acad Sci U S A. 2012 Mar
6;109(10):3879–3884. PMCID: PMC3309757
30.
Schmitz R, Wright GW, Huang DW, Johnson CA,
Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson
DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC,
Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald
A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard
JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S,
Wilson WH, Staudt LM. Genetics and Pathogenesis of
Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018 Apr
12;378(15):1396–1407. PMCID: PMC6010183
31.
Spina V, Khiabanian H, Messina M, Monti S,
Cascione L, Bruscaggin A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni
M, Tabbò F, Zairis S, Diop F, Cerri M, Chiaretti S, Marasca R, Ponzoni
M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B,
Inghirami G, Bertoni F, Foà R, Rabadan R, Gaidano G, Rossi D. The
genetics of nodal marginal zone lymphoma. Blood. 2016 Sep
8;128(10):1362–1373. PMCID: PMC5016706
32.
Zhang J, Dominguez-Sola D, Hussein S, Lee JE,
Holmes AB, Bansal M, Vlasevska S, Mo T, Tang H, Basso K, Ge K,
Dalla-Favera R, Pasqualucci L. Disruption of KMT2D perturbs
germinal center B cell development and promotes
lymphomagenesis. Nat Med. 2015 Oct;21(10):1190–1198. PMCID: PMC5145002
33.
Beà
S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné
E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Croce
LD, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N,
Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L,
Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ,
Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner
A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS,
Campo E. Landscape of
somatic mutations and clonal evolution in mantle cell lymphoma.
PNAS. 2013;110(45):18250–18255.
34.
Johnston JM, Carroll WL. C-myc hypermutation in
Burkitt’s lymphoma. Leuk Lymphoma. 1992
Dec;8(6):431–439.
35.
Freie B, Carroll PA, Varnum-Finney BJ, Ramsey
EL, Ramani V, Bernstein I, Eisenman RN. A germline point mutation in the
MYC-FBW7 phosphodegron initiates hematopoietic
malignancies. Genes Dev. 2024 Apr 17;38(5-6):253–272. PMCID: PMC11065175
36.
Pasqualucci L, Neumeister P, Goossens T,
Nanjangud G, Chaganti RS, Küppers R, Dalla-Favera R. Hypermutation of multiple
proto-oncogenes in B-cell diffuse large-cell
lymphomas. Nature. 2001 Jul 19;412(6844):341–346.
37.
Thomas N, Dreval K, Gerhard DS, Hilton LK,
Abramson JS, Ambinder RF, Barta S, Bartlett NL, Bethony J, Bhatia K,
Bowen J, Bryan AC, Cesarman E, Casper C, Chadburn A, Cruz M, Dittmer DP,
Dyer MA, Farinha P, Gastier-Foster JM, Gerrie AS, Grande BM, Greiner T,
Griner NB, Gross TG, Harris NL, Irvin JD, Jaffe ES, Henry D, Huppi R,
Leal FE, Lee MS, Martin JP, Martin MR, Mbulaiteye SM, Mitsuyasu R,
Morris V, Mullighan CG, Mungall AJ, Mungall K, Mutyaba I, Nokta M,
Namirembe C, Noy A, Ogwang MD, Omoding A, Orem J, Ott G, Petrello H,
Pittaluga S, Phelan JD, Ramos JC, Ratner L, Reynolds SJ, Rubinstein PG,
Sissolak G, Slack G, Soudi S, Swerdlow SH, Traverse-Glehen A, Wilson WH,
Wong J, Yarchoan R, ZenKlusen JC, Marra MA, Staudt LM, Scott DW, Morin
RD. Genetic subgroups inform on pathobiology in adult and pediatric
Burkitt lymphoma. Blood. 2023 Feb 23;141(8):904–916. PMCID:
PMC10023728
38.
Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A,
Wollert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, Dörken B, Janz M,
Dirnhofer S, Lenz P, Hummel M, Tzankov A, Lenz G. PTEN loss
defines a PI3K/AKT pathway-dependent germinal
center subtype of diffuse large B-cell
lymphoma. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12420–12425.
PMCID: PMC3725065
39.
Weber J, de la Rosa J, Grove CS, Schick M, Rad
L, Baranov O, Strong A, Pfaus A, Friedrich MJ, Engleitner T, Lersch R,
Öllinger R, Grau M, Menendez IG, Martella M, Kohlhofer U, Banerjee R,
Turchaninova MA, Scherger A, Hoffman GJ, Hess J, Kuhn LB, Ammon T, Kim
J, Schneider G, Unger K, Zimber-Strobl U, Heikenwälder M,
Schmidt-Supprian M, Yang F, Saur D, Liu P, Steiger K, Chudakov DM, Lenz
G, Quintanilla-Martinez L, Keller U, Vassiliou GS, Cadiñanos J, Bradley
A, Rad R. PiggyBac transposon tools for recessive screening
identify B-cell lymphoma drivers in mice.
Nat Commun. 2019 Mar 29;10(1):1415. PMCID: PMC6440946
40.
O’Hayre M, Inoue A, Kufareva I, Wang Z, Mikelis
CM, Drummond RA, Avino S, Finkel K, Kalim KW, DiPasquale G, Guo F, Aoki
J, Zheng Y, Lionakis MS, Molinolo AA, Gutkind JS. Inactivating mutations
in GNA13 and RHOA in Burkitt’s
lymphoma and diffuse large B-cell lymphoma:
A tumor suppressor function for the Gα13/RhoA
axis in B cells. Oncogene. 2016 Jul 21;35(29):3771–3780.
PMCID: PMC4885800
41.
Chapuy B, Stewart C, Dunford AJ, Kim J,
Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger
AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A,
Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M,
Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan
JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub
TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler
M, Pfreundschuh M, Trümper L, Getz G, Shipp MA. Molecular subtypes of
diffuse large B cell lymphoma are associated with distinct
pathogenic mechanisms and outcomes. Nat Med. 2018 May;24(5):679–690.
PMCID: PMC6613387
42.
Fernando TM, Piskol R, Bainer R, Sokol ES,
Trabucco SE, Zhang Q, Trinh H, Maund S, Kschonsak M, Chaudhuri S,
Modrusan Z, Januario T, Yauch RL. Functional characterization of
SMARCA4 variants identified by targeted exome-sequencing of
131,668 cancer patients. Nat Commun. 2020 Nov 3;11(1):5551. PMCID: PMC7609548
43.
Nadeu F, Martín-García D, Clot G, Díaz-Navarro
A, Duran-Ferrer M, Navarro A, Vilarrasa-Blasi R, Kulis M, Royo R,
Gutiérrez-Abril J, Valdés-Mas R, López C, Chapaprieta V, Puiggrós M,
Castellano G, Costa D, Aymerich M, Jares P, Espinet B, Muntañola A,
Ribera‐Cortada I, Siebert R, Colomer D, Torrents D, Giné E,
López-Guillermo A, Küppers R, Martín-Subero J, Puente X, Beà S, Campo E.
Genomic and
epigenomic insights into the origin, pathogenesis and clinical behavior
of mantle cell lymphoma subtypes. Blood. 2020;
44.
Wilda M, Bruch J, Harder L, Rawer D, Reiter A,
Borkhardt A, Woessmann W. Inactivation of the ARF-MDM-2-p53 pathway in sporadic
Burkitt’s lymphoma in children. Leukemia. 2004
Mar;18(3):584–588.
45.
Kato S, Han SY, Liu W, Otsuka K, Shibata H,
Kanamaru R, Ishioka C. Understanding the function-structure and
function-mutation relationships of P53 tumor suppressor protein by
high-resolution missense mutation analysis. Proc Natl Acad Sci U S A.
2003 Jul 8;100(14):8424–8429. PMCID: PMC166245
46.
Tiacci E, Ladewig E, Schiavoni G, Penson A,
Fortini E, Pettirossi V, Wang Y, Rosseto A, Venanzi A, Vlasevska S,
Pacini R, Piattoni S, Tabarrini A, Pucciarini A, Bigerna B, Santi A,
Gianni AM, Viviani S, Cabras A, Ascani S, Crescenzi B, Mecucci C,
Pasqualucci L, Rabadan R, Falini B. Pervasive mutations of
JAK-STAT pathway genes in classical Hodgkin
lymphoma. Blood. 2018 May 31;131(22):2454–2465. PMCID: PMC6634958
47.
Hübschmann D, Kleinheinz K, Wagener R, Bernhart
SH, López C, Toprak UH, Sungalee S, Ishaque N, Kretzmer H, Kreuz M,
Waszak SM, Paramasivam N, Ammerpohl O, Aukema SM, Beekman R, Bergmann
AK, Bieg M, Binder H, Borkhardt A, Borst C, Brors B, Bruns P, Carrillo
de Santa Pau E, Claviez A, Doose G, Haake A, Karsch D, Haas S, Hansmann
ML, Hoell JI, Hovestadt V, Huang B, Hummel M, Jäger-Schmidt C,
Kerssemakers JNA, Korbel JO, Kube D, Lawerenz C, Lenze D, Martens JHA,
Ott G, Radlwimmer B, Reisinger E, Richter J, Rico D, Rosenstiel P,
Rosenwald A, Schillhabel M, Stilgenbauer S, Stadler PF, Martín-Subero
JI, Szczepanowski M, Warsow G, Weniger MA, Zapatka M, Valencia A,
Stunnenberg HG, Lichter P, Möller P, Loeffler M, Eils R, Klapper W,
Hoffmann S, Trümper L, ICGC MMML-Seq consortium, ICGC DE-Mining
consortium, BLUEPRINT consortium, Küppers R, Schlesner M, Siebert R.
Mutational mechanisms shaping the coding and noncoding genome of
germinal center derived B-cell lymphomas.
Leukemia. 2021 Jul;35(7):2002–2016. PMCID: PMC8257491
48.
Burkhardt B, Michgehl U, Rohde J, Erdmann T,
Berning P, Reutter K, Rohde M, Borkhardt A, Burmeister T, Dave S,
Tzankov A, Dugas M, Sandmann S, Fend F, Finger J, Mueller S, Gökbuget N,
Haferlach T, Kern W, Hartmann W, Klapper W, Oschlies I, Richter J,
Kontny U, Lutz M, Maecker-Kolhoff B, Ott G, Rosenwald A, Siebert R, von
Stackelberg A, Strahm B, Woessmann W, Zimmermann M, Zapukhlyak M, Grau
M, Lenz G. Clinical relevance of molecular characteristics in
Burkitt lymphoma differs according to age. Nat Commun. 2022
Jul 6;13(1):3881. PMCID: PMC9259584
49.
Sarkozy C, Hung SS, Chavez EA, Duns G, Takata
K, Chong LC, Aoki T, Jiang A, Miyata-Takata T, Telenius A, Slack GW,
Molina TJ, Ben-Neriah S, Farinha P, Dartigues P, Damotte D, Mottok A,
Salles GA, Casasnovas RO, Savage KJ, Laurent C, Scott DW,
Traverse-Glehen A, Steidl C. Mutational landscape of
gray zone lymphoma. Blood. 2021 Apr 1;137(13):1765–1776.
50.
Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of
somatic mutations in translocated BCL2 oncogenes of
non-Hodgkin’s lymphomas. Blood. 1992 Jan
1;79(1):229–237.
51.
Almasmoum HA, Airhihen B, Seedhouse C, Winkler
GS. Frequent
loss of BTG1 activity and impaired interactions with the
Caf1 subunit of the Ccr4-Not deadenylase in
non-Hodgkin lymphoma. Leuk Lymphoma. 2021
Feb;62(2):281–290.
52.
Abate F, Ambrosio M, Mundo L, Laginestra M,
Fuligni F, Rossi M, Zairis S, Gazaneo S, Falco GD, Lazzi S, Bellan C,
Rocca BJ, Amato T, Marasco E, Etebari M, Ogwang M, Calbi V, Ndede I,
Patel K, Chumba D, Piccaluga P, Pileri S, Leoncini L, Rabadán R. Distinct
Viral and Mutational Spectrum of Endemic
Burkitt Lymphoma. PLoS Pathogens. 2015;11.
53.
Russler-Germain DA, Krysiak K, Ramirez CA,
Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S,
Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I,
Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger
T. Mutations
associated with progression in follicular lymphoma predict inferior
outcomes at diagnosis: Alliance A151303. Blood
Advances. 2023;7:5524–5539.
54.
Kannengiesser C, Brookes S, del Arroyo AG, Pham
D, Bombled J, Barrois M, Mauffret O, Avril MFM, Chompret A, Lenoir GM,
Sarasin A, French Hereditary Melanoma Study Group, Peters G, Bressac-de
Paillerets B. Functional,
structural, and genetic evaluation of 20 CDKN2A germ line
mutations identified in melanoma-prone families or patients. Hum
Mutat. 2009 Apr;30(4):564–574.
55.
Zmajkovicova K, Pawar S, Maier-Munsa S,
Maierhofer B, Wiest I, Skerlj R, Taveras AG, Badarau A.
Genotype-phenotype correlations in WHIM syndrome: A
systematic characterization of CXCR4WHIM variants. Genes
Immun. 2022 Sep;23(6):196–204. PMCID: PMC9519442
56.
Khodabakhshi AH, Morin RD, Fejes AP, Mungall
AJ, Mungall KL, Bolger-Munro M, Johnson NA, Connors JM, Gascoyne RD,
Marra MA, Birol I, Jones SJM. Recurrent targets of aberrant somatic
hypermutation in lymphoma. Oncotarget. 2012;3(11):1308–1319. PMCID: PMC3717795
57.
Ramírez-Komo JA, Delaney MA, Straign D, Lukin
K, Tsang M, Iritani BM, Hagman J. Spontaneous loss of B
lineage transcription factors leads to pre-B leukemia in
Ebf1+/-Bcl-xLTg mice.
Oncogenesis. 2017 Jul 10;6(7):e355. PMCID: PMC5541707
58.
Bohle V, Döring C, Hansmann M-L, Küppers R. Role of early B-cell factor 1 (EBF1) in
Hodgkin lymphoma. Leukemia. 2013 Mar;27(3):671–679.
59.
Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK,
Pollock RM, Richon VM, Copeland RA. Coordinated activities of wild-type
plus mutant EZH2 drive tumor-associated hypertrimethylation
of lysine 27 on histone H3 (H3K27) in human
B-cell lymphomas. Proc Natl Acad Sci U S A.
2010 Dec 7;107(49):20980–20985. PMCID: PMC3000297
60.
Morin RD, Johnson NA, Severson TM, Mungall AJ,
An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D,
Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, Shashkin P, Charlot
JF, Tcherpakov M, Corbett R, Tam A, Varhol R, Smailus D, Moksa M, Zhao
Y, Delaney A, Qian H, Birol I, Schein J, Moore R, Holt R, Horsman DE,
Connors JM, Jones S, Aparicio S, Hirst M, Gascoyne RD, Marra MA. Somatic
mutations altering EZH2 (Tyr641) in follicular
and diffuse large B-cell lymphomas of
germinal-center origin. Nat Genet. 2010 Feb;42(2):181–185. PMCID: PMC2850970
61.
Lazarian G, Yin S, Ten Hacken E, Sewastianik T,
Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L,
Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ,
Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak
KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJ. A
hotspot mutation in transcription factor IKZF3 drives
B cell neoplasia via transcriptional dysregulation. Cancer
Cell. 2021 Mar 8;39(3):380–393.e8. PMCID: PMC8034546
62.
Qiu
Z, Khalife J, Ethiraj P, Jaafar C, Lin AP, Holder KN, Ritter JP, Chiou
L, Huelgas-Morales G, Aslam S, Zhang Z, Liu Z, Arya S, Gupta YK, Dahia
PLM, Aguiar RCT. IRF8-mutant B cell lymphoma
evades immunity through a CD74-dependent
deregulation of antigen processing and presentation in
MHCII complexes. Sci Adv. 2024 Jul 12;10(28):eadk2091.
PMCID: PMC11244530
63.
Zhou P, Blain AE, Newman AM, Zaka M, Chagaluka
G, Adlar FR, Offor UT, Broadbent C, Chaytor L, Whitehead A, Hall A,
O’Connor H, Van Noorden S, Lampert I, Bailey S, Molyneux E, Bacon CM,
Bomken S, Rand V. Sporadic and endemic Burkitt lymphoma
have frequent FOXO1 mutations but distinct hotspots in the
AKT recognition motif. Blood Adv. 2019 Jul
23;3(14):2118–2127. PMCID: PMC6650741
64.
Zhang J, Jima D, Moffitt AB, Liu Q, Czader M,
Hsi ED, Fedoriw Y, Dunphy CH, Richards KL, Gill JI, Sun Z, Love C,
Scotland P, Lock E, Levy S, Hsu DS, Dunson D, Dave SS. The genomic
landscape of mantle cell lymphoma is related to the epigenetically
determined chromatin state of normal B cells. Blood.
2014 May 8;123(19):2988–2996.
65.
Trissal MC, Wong TN, Yao JC, Ramaswamy R, Kuo
I, Baty J, Sun Y, Jih G, Parikh N, Berrien-Elliott MM, Fehniger TA, Ley
TJ, Maillard I, Reddy PR, Link DC. MIR142
Loss-of-Function Mutations Derepress ASH1L to Increase HOXA
Gene Expression and Promote Leukemogenesis. Cancer
Res. 2018 Jul 1;78(13):3510–3521. PMCID: PMC6030481
66.
Kwanhian W, Lenze D, Alles J, Motsch N, Barth
S, Döll C, Imig J, Hummel M, Tinguely M, Trivedi P, Lulitanond V,
Meister G, Renner C, Grässer FA. MicroRNA-142 is mutated in
about 20% of diffuse large B-cell lymphoma.
Cancer Med. 2012 Oct;1(2):141–155. PMCID: PMC3544448
67.
Kuo
HP, Ezell SA, Hsieh S, Schweighofer KJ, Cheung LW, Wu S, Apatira M,
Sirisawad M, Eckert K, Liang Y, Hsu J, Chen CT, Beaupre D, Chang BY. The
role of PIM1 in the ibrutinib-resistant ABC
subtype of diffuse large B-cell lymphoma. Am
J Cancer Res. 2016;6(11):2489–2501. PMCID: PMC5126268
68.
Fan
Z, Pei R, Sha K, Chen L, Wang T, Lu Y. Comprehensive characterization of
driver genes in diffuse large B cell lymphoma. Oncol Lett.
2020 Jul;20(1):382–390. PMCID: PMC7285964
69.
Asmar F, Punj V, Christensen J, Pedersen MT,
Pedersen A, Nielsen AB, Hother C, Ralfkiaer U, Brown P, Ralfkiaer E,
Helin K, Grønbæk K. Genome-wide profiling identifies a DNA
methylation signature that associates with TET2 mutations
in diffuse large B-cell lymphoma.
Haematologica. 2013 Dec;98(12):1912–1920. PMCID: PMC3856967
70.
Albuquerque MA, Grande BM, Ritch EJ,
Pararajalingam P, Jessa S, Krzywinski M, Grewal JK, Shah SP, Boutros PC,
Morin RD. Enhancing knowledge discovery from cancer genomics data with
Galaxy. Gigascience. 2017 May 1;6(5):1–13. PMCID: PMC5437943
71.
Wan
PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM,
Marshall CJ, Springer CJ, Barford D, Marais R, Cancer Genome Project. Mechanism of
activation of the RAF-ERK signaling pathway by oncogenic
mutations of B-RAF. Cell. 2004 Mar 19;116(6):855–867.
72.
Tiacci E, Trifonov V, Schiavoni G, Holmes A,
Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA,
Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti
A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M,
Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C,
Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L,
Rabadan R, Falini B. BRAF mutations in hairy-cell leukemia.
N Engl J Med. 2011 Jun 16;364(24):2305–2315. PMCID: PMC3689585
73.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM,
Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL,
Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G,
Müller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM,
Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel
RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.
Chronic active B-cell-receptor signalling in
diffuse large B-cell lymphoma. Nature. 2010
Jan;463(7277):88–92. PMCID: PMC2845535
74.
Gomez F, Fisk B, McMichael JF, Mosior M, Foltz
JA, Skidmore ZL, Duncavage EJ, Miller CA, Abel H, Li YS, Russler-Germain
DA, Krysiak K, Watkins MP, Ramirez CA, Schmidt A, Martins Rodrigues F,
Trani L, Khanna A, Wagner JA, Fulton RS, Fronick CC, O’Laughlin MD,
Schappe T, Cashen AF, Mehta-Shah N, Kahl BS, Walker J, Bartlett NL,
Griffith M, Fehniger TA, Griffith OL. Ultra-Deep Sequencing
Reveals the Mutational Landscape of Classical
Hodgkin Lymphoma. Cancer Res Commun. 2023 Nov 15;3(11):2312–2330.
PMCID: PMC10648575
75.
Grabiner BC, Nardi V, Birsoy K, Possemato R,
Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM. A diverse array of
cancer-associated MTOR mutations are hyperactivating and
can predict rapamycin sensitivity. Cancer Discov. 2014 May;4(5):554–563.
PMCID: PMC4012430
76.
Ryan RJH, Petrovic J, Rausch DM, Zhou Y, Lareau
CA, Kluk MJ, Christie AL, Lee WY, Tarjan DR, Guo B, Donohue LKH,
Gillespie SM, Nardi V, Hochberg EP, Blacklow SC, Weinstock DM, Faryabi
RB, Bernstein BE, Aster JC, Pear WS. A B Cell Regulome Links
Notch to Downstream Oncogenic Pathways in
Small B Cell Lymphomas. Cell Rep. 2017 Oct
17;21(3):784–797. PMCID: PMC5687286
77.
Pasqualucci L, Trifonov V, Fabbri G, Ma J,
Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J,
Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera
R. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011 Jul
31;43(9):830–837. PMCID: PMC3297422
78.
Cazzola M, Rossi M, Malcovati L, Associazione
Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie
Mieloproliferative. Biologic and clinical significance of somatic
mutations of SF3B1 in myeloid and lymphoid neoplasms.
Blood. 2013 Jan 10;121(2):260–269. PMCID: PMC3790951


